Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-28 Mln
ROE
-13.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
19.1
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
2,947,660
CFO
$-282.12 Mln
EBITDA
$-299.80 Mln
Net Profit
$-335.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Axcella Health (AXLA)
| -95.1 | -68.9 | -96.2 | -94.9 | -85.5 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Axcella Health (AXLA)
| -95.1 | -84.3 | -59.7 | 29.4 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Axcella Health (AXLA)
|
0.4 | 1.2 | 0.0 | -50.0 | -- | -- | -- | 19.1 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long... COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts. Read more
Pres, CEO & Director
Mr. William R. Hinshaw Jr.
Pres, CEO & Director
Mr. William R. Hinshaw Jr.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Axcella Health Inc (AXLA) is $0.40 (NASDAQ) as of 29-Dec-2023 16:00 EDT. Axcella Health Inc (AXLA) has given a return of -85.51% in the last 3 years.
Since, TTM earnings of Axcella Health Inc (AXLA) is negative, P/E ratio is not available.
The P/B ratio of Axcella Health Inc (AXLA) is 19.10 times as on 29-Dec-2023, a 385 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.22
|
4.28
|
|
2021
|
-1.21
|
3.69
|
|
2020
|
-3.31
|
2.58
|
|
2019
|
-1.55
|
1.54
|
|
2018
|
--
|
--
|
The 52-week high and low of Axcella Health Inc (AXLA) are Rs -- and Rs -- as of 04-Apr-2026.
Axcella Health Inc (AXLA) has a market capitalisation of $ 1 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Before investing in Axcella Health Inc (AXLA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.